Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data
Xenon Pharmaceuticals Inc.'s XEN1101 shows promise in epilepsy with strong phase 2b results and solid financials. Click here ...
Xenon Slides Ahead of San Diego Concference
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares lost ground Friday, as the neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing ...
The Manila Times15h
Vimeo Announces 'Vimeo Streaming': a New Era of Video Monetization, Control, and Discovery on Every Screen
Introducing Vimeo Streaming - Now, any creator, big or small can launch their own streaming services and branded apps, and deliver a next-generation experience for their global audiences. Vimeo ...
Le Lézard16h
Aladdin Foods brand Lean Ground Beef recalled due to E.coli O103
Food - Microbial contamination - E. Coli - other pathogenic DistributionOntario Online link SOURCE Canadian Food Inspection Agency (CFIA) ...
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025
Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meetingLong-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in focal onset ...
The full list of 8,000 US products the UK could impose tariffs on
The government has drawn up a list of US products that could be subject to tariffs in a retaliatory response to Donald ...
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $57.38 Average Target Price from Brokerages
Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) have been given an average rating of “Buy” by the nine analysts that are currently covering the firm, MarketBeat.com reports. Nine ...